MV 0633

Drug Profile

MV 0633

Latest Information Update: 19 Nov 2010

Price : $50

At a glance

  • Originator Miravant Medical Technologies
  • Class Cardiovascular therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Coronary artery restenosis; Vascular restenosis

Most Recent Events

  • 19 Nov 2010 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
  • 19 Nov 2010 Discontinued - Preclinical for Coronary artery restenosis in USA (Intracoronary)
  • 19 Nov 2010 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top